Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRY-box transcription factor 21 (SOX21) is a DNA-binding transcription factor of the SOX family, characterized by a high-mobility group (HMG) domain. It is implicated in neuronal differentiation, antagonizing other SOX proteins that maintain neural stem cell states, and plays a role in hair follicle formation, with genetic variants linked to congenital hair loss syndromes. SOX21 also contributes to tissue-specific differentiation like ameloblast formation and is associated with multiple human diseases. The antisense RNA transcript, SOX21-AS1, functions as a long non-coding RNA that regulates gene expression, cellular proliferation, apoptosis, migration, EMT, and stemness via diverse signaling pathways. SOX21-AS1 is emerging as a biomarker and therapeutic target, especially in cancer and Alzheimer’s disease, modulating drug resistance and disease progression through ceRNA activity and post-transcriptional regulation mechanisms
Gene silencing or modulation of RNA expression (for lncRNA SOX21-AS1), modulation of signaling pathways (PI3K/AKT, ERK, Hippo, Wnt/β-catenin), microRNA sponging (e.g., miR-107, miR-132 for SOX21-AS1)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRY-box transcription factor 21 (SOX21).